Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.
Fätkenheuer G, Jessen H, Stoehr A, Jung N, Jessen AB, Kümmerle T, Berger M, Bogner JR, Spinner CD, Stephan C, Degen O, Vogelmann R, Spornraft-Ragaller P, Schnaitmann E, Jensen B, Ulmer A, Kittner JM, Härter G, Malfertheiner P, Rockstroh J, Knecht G, Scholten S, Harrer T, Kern WV, Salzberger B, Schürmann D, Ranneberg B. Fätkenheuer G, et al. Among authors: scholten s. HIV Med. 2016 Jun;17(6):453-9. doi: 10.1111/hiv.12363. Epub 2016 May 11. HIV Med. 2016. PMID: 27166295 Free article. Clinical Trial.
Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT Study.
Boesecke C, Singh GKJ, Scholten SH, Lutz T, Baumgarten A, Schneeweiss SM, Trein A, Rausch M, Ingiliz P, Rockstroh JK, Nelson M; CHAT study group. Boesecke C, et al. Antivir Ther. 2017;22(7):619-623. doi: 10.3851/IMP3143. Epub 2017 Feb 27. Antivir Ther. 2017. PMID: 28240597 Clinical Trial.
Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK. Bischoff J, et al. Among authors: scholten s. HIV Med. 2018 Apr;19(4):299-307. doi: 10.1111/hiv.12579. Epub 2018 Jan 25. HIV Med. 2018. PMID: 29368456 Free article.
Summary of German-Austrian HIV PrEP guideline.
Spinner CD, Lang GF, Boesecke C, Jessen H, Schewe K; German-Austrian PrEP consensus conference meeting 2018. Spinner CD, et al. HIV Med. 2019 Jul;20(6):368-376. doi: 10.1111/hiv.12724. Epub 2019 May 29. HIV Med. 2019. PMID: 31140708 Free article.
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.
Pantke A, Kollan C, Gunsenheimer-Bartmeyer B, Jensen BO, Stephan C, Degen O, Schürmann D, Kurth T, Bremer V, Koppe U; HIV-1 Seroconverter Cohort and the ClinSurv HIV Cohort. Pantke A, et al. Infection. 2024 Apr;52(2):637-648. doi: 10.1007/s15010-024-02188-y. Epub 2024 Feb 21. Infection. 2024. PMID: 38381307 Free PMC article.
140 results